Actelion (Actelion) ROE % Adjusted to Book Value : 2.97% (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion ROE % Adjusted to Book Value?

Actelion's ROE % for the quarter that ended in Mar. 2017 was 54.05%. Actelion's PB Ratio for the quarter that ended in Mar. 2017 was 18.22. Actelion's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2017 was 2.97%.

Actelion ROE % Adjusted to Book Value Historical Data

The historical data trend for Actelion's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion ROE % Adjusted to Book Value Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

6.20

5.72

4.73

3.09

3.01

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															4.98	4.53	5.02	1.97	2.97

Competitive Comparison of Actelion's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Actelion's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actelion's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Actelion's ROE % Adjusted to Book Value falls into.

Actelion ROE % Adjusted to Book Value Calculation

Actelion's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2016 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	52.06%	/	17.29
	=	3.01%

Actelion's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2017 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	54.05%	/	18.22
	=	2.97%

Actelion ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Actelion's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017